# Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

> **NCT01721109** · PHASE2,PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 50 (actual)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- HIV Infections

## Interventions

- **DRUG:** EVG/COBI/FTC/TDF

## Key facts

- **NCT ID:** NCT01721109
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-06
- **Primary completion:** 2015-10-22
- **Final completion:** 2018-01-29
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721109, "Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01721109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*